4//SEC Filing
TAKANASHI KEN 4
Accession 0000899243-19-023732
CIK 0001692830other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 4:05 PM ET
Size
14.7 KB
Accession
0000899243-19-023732
Insider Transaction Report
Form 4
TAKANASHI KEN
Director10% Owner
Transactions
- Purchase
Common Stock, $0.0001 par value
2019-09-17$15.00/sh+233,333$3,499,995→ 1,561,719 total(indirect: See FN) - Conversion
Common Stock, $0.0001 par value
2019-09-17+33,741→ 1,021,276 total(indirect: See FN) - Conversion
Common Stock, $0.0001 par value
2019-09-17+307,110→ 1,328,386 total(indirect: See FN) - Conversion
Series B Preferred Stock
2019-09-17−307,110→ 0 total(indirect: See FN)→ Common Stock (307,110 underlying) - Conversion
Series A Preferred Stock
2019-09-17−33,741→ 0 total(indirect: See FN)→ Common Stock (33,741 underlying)
Footnotes (4)
- [F1]Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the Issuer's initial public offering.
- [F2]Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of Issuer's initial public offering.
- [F3]Shares are held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL"). Mr. Takanashi, a director of the Issuer, is a director and executive officer of SNBL and its affiliates such that Mr. Takanashi may be deemed to hold the power to direct the disposition and vote of, and therefore to own the shares held by SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL except to the extent of any actual pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.
- [F4]SNBL USA, Ltd., a subsidiary of SNBL, purchased an additional 233,333 shares of issuer's common stock in connection with the initial public offering at the offering price of $15.00 per share.
Documents
Issuer
Satsuma Pharmaceuticals, Inc.
CIK 0001692830
Entity typeother
Related Parties
1- filerCIK 0001657768
Filing Metadata
- Form type
- 4
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 4:05 PM ET
- Size
- 14.7 KB